333 related articles for article (PubMed ID: 28974896)
1. Access to biologicals in Crohn's disease in ten European countries.
Péntek M; Lakatos PL; Oorsprong T; Gulácsi L; Pavlova M; Groot W; Rencz F; Brodszky V; Baji P; Crohn's Disease Research Group
World J Gastroenterol; 2017 Sep; 23(34):6294-6305. PubMed ID: 28974896
[TBL] [Abstract][Full Text] [Related]
2. Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe.
Rencz F; Péntek M; Bortlik M; Zagorowicz E; Hlavaty T; Śliwczyński A; Diculescu MM; Kupcinskas L; Gecse KB; Gulácsi L; Lakatos PL
World J Gastroenterol; 2015 Feb; 21(6):1728-37. PubMed ID: 25684937
[TBL] [Abstract][Full Text] [Related]
3. Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe.
Rencz F; Gulácsi L; Péntek M; Gecse KB; Dignass A; Halfvarson J; Gomollón F; Baji P; Peyrin-Biroulet L; Lakatos PL; Brodszky V
Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):597-606. PubMed ID: 28434387
[TBL] [Abstract][Full Text] [Related]
4. Treatment preferences of originator versus biosimilar drugs in Crohn's disease; discrete choice experiment among gastroenterologists.
Baji P; Gulácsi L; Lovász BD; Golovics PA; Brodszky V; Péntek M; Rencz F; Lakatos PL
Scand J Gastroenterol; 2016 Jan; 51(1):22-7. PubMed ID: 26059967
[TBL] [Abstract][Full Text] [Related]
5. A budget impact model for biosimilar infliximab in Crohn's disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia.
Brodszky V; Rencz F; Péntek M; Baji P; Lakatos PL; Gulácsi L
Expert Rev Pharmacoecon Outcomes Res; 2016; 16(1):119-25. PubMed ID: 26162458
[TBL] [Abstract][Full Text] [Related]
6. Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries.
Gulácsi L; Rencz F; Péntek M; Brodszky V; Lopert R; Hevér NV; Baji P
Eur J Health Econ; 2014 May; 15 Suppl 1():S27-34. PubMed ID: 24832833
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderate-Severe Crohn's Disease in Biologic-Naïve Patients.
Aliyev ER; Hay JW; Hwang C
Pharmacotherapy; 2019 Feb; 39(2):118-128. PubMed ID: 30565265
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness Analysis of Crohn's Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist.
Holko P; Kawalec P; Pilc A
Pharmacoeconomics; 2018 Jul; 36(7):853-865. PubMed ID: 29667146
[TBL] [Abstract][Full Text] [Related]
9. Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe.
Malinowski KP; Kawalec P; Trąbka W; Sowada C; Petrova G; Manova M; Savova A; Draganić P; Slabý J; Männik A; Márky K; Rugaja Z; Gulbinovic J; Tesar T; Paveliu MS
Orphanet J Rare Dis; 2020 Oct; 15(1):277. PubMed ID: 33032634
[TBL] [Abstract][Full Text] [Related]
10. The Economic Impact of the Introduction of Biosimilars in Inflammatory Bowel Disease.
Severs M; Oldenburg B; van Bodegraven AA; Siersema PD; Mangen MJ;
J Crohns Colitis; 2017 Mar; 11(3):289-296. PubMed ID: 27571772
[TBL] [Abstract][Full Text] [Related]
11. Infliximab paediatric Crohn's disease educational plan: a European, cross-sectional, multicentre evaluation.
Arana A; Allen S; Burkowitz J; Fantoni V; Ghatnekar O; Rico MT; Vanhaverbeke N; Wentworth CE; Brosa M; Arellano FM
Drug Saf; 2010 Jun; 33(6):489-501. PubMed ID: 20486731
[TBL] [Abstract][Full Text] [Related]
12. Influence of biosimilar infliximab launch on the utilization pattern of biological medicines: the case of Hungary.
Harsányi A; Csanádi M; Márky K; Vincziczki ÁZ; Kaló Z; Inotai A
Expert Rev Pharmacoecon Outcomes Res; 2020 Dec; 20(6):653-659. PubMed ID: 31510811
[No Abstract] [Full Text] [Related]
13. Perceived Risks Contra Benefits of Using Biosimilar Drugs in Ulcerative Colitis: Discrete Choice Experiment among Gastroenterologists.
Baji P; Gulácsi L; Golovics PA; Lovász BD; Péntek M; Brodszky V; Rencz F; Lakatos PL
Value Health Reg Issues; 2016 Sep; 10():85-90. PubMed ID: 27881284
[TBL] [Abstract][Full Text] [Related]
14. Health Economic Data Requirements and Availability in the European Union: Results of a Survey Among 10 European Countries.
Skoupá J; Annemans L; Hájek P
Value Health Reg Issues; 2014 Sep; 4():53-57. PubMed ID: 29702807
[TBL] [Abstract][Full Text] [Related]
15. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
Burisch J
Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
[TBL] [Abstract][Full Text] [Related]
16. Resource use and cost of care with biologicals in Crohn's disease in South Africa: a retrospective analysis from a payer perspective.
Miot J; Smith S; Bhimsan N
Int J Clin Pharm; 2016 Aug; 38(4):880-7. PubMed ID: 27118462
[TBL] [Abstract][Full Text] [Related]
17. Adherence of gastroenterologists to European Crohn's and Colitis Organisation consensus on Crohn's disease: a real-life survey in Spain.
Hinojosa J; Gisbert JP; Gomollón F; López San Román A
J Crohns Colitis; 2012 Aug; 6(7):763-70. PubMed ID: 22398092
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of biological therapy in pediatric patients with Crohn's disease.
Tarnok A; Kiss Z; Kadenczki O; Veres G
Expert Opin Biol Ther; 2019 Mar; 19(3):181-196. PubMed ID: 30601083
[TBL] [Abstract][Full Text] [Related]
19. More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments.
Kandolf Sekulovic L; Peris K; Hauschild A; Stratigos A; Grob JJ; Nathan P; Dummer R; Forsea AM; Hoeller C; Gogas H; Demidov L; Lebbe C; Blank C; Olah J; Bastholt L; Herceg D; Neyns B; Vieira R; Hansson J; Rutkowski P; Krajsova I; Bylaite-Bucinskiene M; Zalaudek I; Maric-Brozic J; Babovic N; Banjin M; Putnik K; Weinlich G; Todorovic V; Kirov K; Ocvirk J; Zhukavets A; Kukushkina M; De La Cruz Merino L; Ymeri A; Risteski M; Garbe C
Eur J Cancer; 2017 Apr; 75():313-322. PubMed ID: 28264791
[TBL] [Abstract][Full Text] [Related]
20. Inequalities in medicine use in Central Eastern Europe: an empirical investigation of socioeconomic determinants in eight countries.
Vogler S; Österle A; Mayer S
Int J Equity Health; 2015 Nov; 14():124. PubMed ID: 26541292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
